ESP or OST-PTP phosphatase dephosphorylates and inactivates the osteoblast insulin receptor and inhibits the metabolic function of osteocalcin, resulting in reduced insulin secretion, hyperglycemia and reduced glucose tolerance [124]. Here, INS is linked to Hyperglycemia.